


COMPANY OVERVIEW

ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. Our lysin and monoclonal antibody platforms target conserved regions of bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (methicillin resistant *Staph aureus*) and influenza.



CONTRAFECT CORPORATION

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
US

RECENT NEWS

ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 16 2019, 5:15 AM EDT

ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

Apr 8 2019, 7:00 AM EDT

ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 4 2019, 7:00 AM EDT

STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	42.13m
Last Price	\$0.5306
52-Week Range	\$0.355 - \$2.9266

04/18/2019 04:00 PM EDT

INVESTOR RELATIONS

Michael Messinger
T: 914-207-2300
mmessinger@contrafect.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.